selegiline has been researched along with Huntington Disease in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (50.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bolognesi, ML; Cavalli, A; Melchiorre, C; Minarini, A; Recanatini, M; Rosini, M; Tumiatti, V | 1 |
| Jellinger, K; Riederer, P | 1 |
| Zaleska, B | 1 |
| Asnis, J; Patel, SV; Tariot, PN | 1 |
2 review(s) available for selegiline and Huntington Disease
| Article | Year |
|---|---|
Multi-target-directed ligands to combat neurodegenerative diseases.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Binding Sites; Calcium Channel Blockers; Chelating Agents; Cholinesterase Inhibitors; Humans; Huntington Disease; Ligands; Multiple Sclerosis; Neurodegenerative Diseases; Neurofibrillary Tangles; Neurotransmitter Agents; Parkinson Disease; Plaque, Amyloid | 2008 |
[Progress in the treatment of degenerative diseases of the nervous system. Selected problems].
Topics: Amyotrophic Lateral Sclerosis; Antiparkinson Agents; Humans; Huntington Disease; Lithium; Neostigmine; Parkinson Disease; Penicillamine; Phthalazines; Selegiline; Tetrabenazine; Tiapamil Hydrochloride | 1980 |
2 other study(ies) available for selegiline and Huntington Disease
| Article | Year |
|---|---|
Neurochemical insights into monoamine oxidase inhibitors, with special reference to deprenyl (selegiline).
Topics: Aged; Aging; Alzheimer Disease; Brain; Central Nervous System; Female; Humans; Huntington Disease; Male; Middle Aged; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurotransmitter Agents; Parkinson Disease; Phenethylamines; Selegiline | 1983 |
L-Deprenyl augmentation of fluoxetine in a patient with Huntington's disease.
Topics: Adult; Anticonvulsants; Antidepressive Agents, Second-Generation; Attention; Carbamazepine; Depression; Drug Interactions; Drug Therapy, Combination; Expressed Emotion; Female; Fluoxetine; Humans; Huntington Disease; Impulsive Behavior; Monoamine Oxidase Inhibitors; Movement; Selegiline; Violence | 1996 |